Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes

Cancer Prevention Research

Volumn 9, Issue 12, 2016, Pages 915-924

  Guerrero Preston, Rafael ^a,b   Valle, Blanca L ^a   Jedlicka, Anne ^c   Turaga, Nitesh ^a   Folawiyo, Oluwasina ^a   Pirini, Francesca ^a   Lawson, Fahcina ^a   Vergura, Angelo ^a   Noordhuis, Maartje ^a,d   Dziedzic, Amanda ^c   Perez, Gabriela ^a   Renehan, Marisa ^a   Guerrero Diaz, Carolina ^a   Jesus Rodríguez, Edgar De ^b   Diaz Montes, Teresa ^e   Orengo, Jose Rodríguez ^b   Mendez, Keimari ^b   Romaguera, Josefina ^b   Trock, Bruce J ^a   Florea, Liliana ^a   Sidransky, David ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Institute for Cancer Care at Mercy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; DNA BINDING PROTEIN; FK 506 BINDING PROTEIN; FKBP6 PROTEIN, HUMAN; L1(DELTAN26)-E7(DELTAC38) PROTEIN, HPV16; TUMOR MARKER; VIRUS DNA; VIRUS LIKE PARTICLE VACCINE; WNT1 PROTEIN; WNT1 PROTEIN, HUMAN; ZNF516 PROTEIN, HUMAN;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; FEMALE; FKBP6 GENE; GENE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INTS1 GENE; NEXT GENERATION SEQUENCING; NONHUMAN; PRECANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINE; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX EPITHELIUM; WART VIRUS; ZNF516 GENE; ADOLESCENT; ADULT; AGED; BIOPSY; BLOOD; COLPOSCOPY; GENETICS; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROSPECTIVE STUDY; UTERINE CERVIX TUMOR; VAGINA SMEAR; VERY ELDERLY; VIROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; COLPOSCOPY; DNA METHYLATION; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TACROLIMUS BINDING PROTEINS; UTERINE CERVICAL NEOPLASMS; VACCINES, VIRUS-LIKE PARTICLE; VAGINAL SMEARS; WNT1 PROTEIN;

EID: 85008415004     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-16-0138     Document Type: Article

References (52)

1. Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, et al. The low risk of precancer after a screening result of human papillomavirusnegative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. Cancer Cytopathol 2014;122:842-50.
2. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011;103:368-83.
3. Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 2014;106:pii: dju153.
4. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78-88.
5. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Rozendaal L, Heideman DA, et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012;106:975-81.
6. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-42.
7. Vink MA, Bogaards JA, Meijer CJ, Berkhof J. Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended? Int J Cancer 2015;137:420-7.
8. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risks of CIN 3\+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis 2013;17: S56-63.
9. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013;121:829-46.
10. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130: 602-10.
11. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. J Low Genit Tract Dis 2013;17:S78-84.
12. Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev 2013;22:553-60.
13. American College of O, Gynecologists. ACOG Practice Bulletin No. 99: management of abnormal cervical cytology and histology. Obstet Gynecol 2008;112:1419-44.
14. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.
15. Castle PE, Gage JC, Wheeler CM, Schiffman M. The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy. Obstet Gynecol 2011; 118:1222-9.
16. Vasiljevic N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol Oncol 2014;132:709-14.
17. Lendvai A, Johannes F, Grimm C, Eijsink JJ, Wardenaar R, Volders HH, et al. Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics 2012;7: 1268-78.
18. Eijsink JJ, Lendvai A, Deregowski V, Klip HG, Verpooten G, Dehaspe L, et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer 2012;130:1861-9.
19. Brebi P, Maldonado L, NoordhuisMG, Ili C, Leal P, Garcia P, et al. Genomewide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population. Epigenetics 2014;9:308-17.
20. Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, et al. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics 2016;8:29.
21. Mirabello L, Schiffman M, Ghosh A, Rodriguez AC, Vasiljevic N, WentzensenN, et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer 2013;132:1412-22.
22. Wentzensen N, Sun C, Ghosh A, KinneyW, Mirabello L, Wacholder S, et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012;104:1738-49.
23. Mirabello L, Sun C, Ghosh A, Rodriguez AC, Schiffman M, Wentzensen N, et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012; 104:556-65.
24. Sun C, Reimers LL, Burk RD. Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. Gynecol Oncol 2011;121: 59-63.
25. Vasiljevic N, Scibior-Bentkowska D, Brentnall A, Cuzick J, Lorincz A. A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers. J Clin Virol 2014; 59:161-6.
26. Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Szarewski A, et al. A DNA methylation classifier of cervical precancer based on human papillomavirus andhuman genes. Int JCancer 2014;135:1425-32.
27. Verhoef VM, van Kemenade FJ, Rozendaal L, Heideman DA, Bosgraaf RP, Hesselink AT, et al. Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes. Gynecol Oncol 2015;137:55-9.
28. Verhoef VM, Heideman DA, van Kemenade FJ, Rozendaal L, Bosgraaf RP, Hesselink AT, et al. Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer. Gynecol Oncol 2014;135:58-63.
29. Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA, Hesselink AT, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 2014;15:315-22.
30. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
31. Mendez K, Romaguera J, Ortiz AP, Lopez M, Steinau M, Unger ER. Urinebased human papillomavirus DNA testing as a screening tool for cervical cancer in high-risk women. Int J Gynaecol Obstet 2014;124:151-5.
32. Sahasrabuddhe VV, Gravitt PE, Dunn ST, Brown D, Allen RA, Eby YJ, et al. Comparison of human papillomavirus detections in urine, vulvar, and cervical samples from women attending a colposcopy clinic. J Clin Microbiol 2014;52:187-92.
33. Vorsters A, Van den Bergh J, Micalessi I, Biesmans S, Bogers J, Hens A, et al. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis 2014; 33:2005-14.
34. Vorsters A, Micalessi I, Bilcke J, IevenM, Bogers J, Van Damme P. Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol Infect Dis 2012;31:627-40.
35. Ducancelle A, Legrand MC, Pivert A, Veillon P, Le Guillou-Guillemette H, De Brux MA, et al. Interest of Human Papillomavirus DNA quantification and genotyping in paired cervical and urine samples to detect cervical lesions. Arch Gynecol Obstet 2014;290:299-308.
36. Lichtenstein AV, Melkonyan HS, Tomei LD, Umansky SR. Circulating nucleic acids and apoptosis. Ann N Y Acad Sci 2001;945:239-49.
37. Van Doorslaer K, TanQ, Xirasagar S, Bandaru S, Gopalan V, Mohamoud Y, et al. The Papillomavirus Episteme: a central resource for papillomavirus sequence data and analysis. Nucleic Acids Res 2013;41:D571-8.
38. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 2011;27:1571-2.
39. Florea L, McClelland M, Riemer C, Schwartz S, Miller W. EnteriX 2003: visualization tools for genome alignments of Enterobacteriaceae. Nucleic Acids Res 2003;31:3527-32.
40. Park IS, Chang X, Loyo M, WuG, Chuang A, Kim MS, et al. Characterization of themethylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers. Cancer Prev Res 2011;4:207-17.
41. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012;9:357-9.
42. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-402.
43. Florea L, Guerrero-Preston R. Large-scale HPV DNA server: Cloud-based visualization tools for personalized cervical cancer screening. 2014 [cited 2016 May 1]. Available from: http://enterix. cbcb. umd. edu/enteric/enteric-hpv. html.
44. Florea L, Guerrero-Preston R. "Close-up" HPV DNA server: Cloud-based visualization tools for personalized cervical cancer screening. 2014 [cited 2016 May 1]. Available from: http://enterix. cbcb. umd. edu/enteric/enteric-hpv. html.
45. Thompson PM, Stein JL, Medland SE, Hibar DP, Vasquez AA, Renteria ME, et al. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav 2014;8:153-82.
46. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
47. Su YH, Wang M, Block TM, Landt O, Botezatu I, Serdyuk O, et al. Transrenal DNA as a diagnostic tool: important technical notes. Ann N Y Acad Sci 2004;1022:81-9.
48. Shekhtman EM, Anne K, Melkonyan HS, Robbins DJ, Warsof SL, Umansky SR. Optimization of transrenal DNA analysis: detection of fetal DNA in maternal urine. Clin Chem 2009;55:723-9.
49. Melkonyan HS, Feaver WJ, Meyer E, Scheinker V, Shekhtman EM, Xin Z, et al. Transrenal nucleic acids: from proof of principle to clinical tests. Ann N Y Acad Sci 2008;1137:73-81.
50. Sahasrabuddhe VV, Gravitt PE, Dunn ST, Robbins D, Brown D, Allen RA, et al. Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. J Clin Virol 2014;60:414-7.
51. Steinau M, Onyekwuluje JM, Scarbrough MZ, Unger ER, Dillner J, Zhou T. Performance of commercial reverse line blot assays for human papillomavirus genotyping. J Clin Microbiol 2012;50:1539-44.
52. Brown AJ, Trimble CL. New technologies for cervical cancer screening. Best Pract Res Clin Obstet Gynaecol 2012;26:233-42.